Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals

The final rule maintains separate payment for advanced diagnostic imaging agents and confirms PYLARIFY TruVu’s transitional pass-through status through September 30, 2029. Permanent HCPCS code A9613 is now in effect.

Analysis

The economic value is reimbursement certainty, not the code itself: separate payment can reduce hospitals’ incentive to avoid an advanced imaging agent when its cost is otherwise absorbed into a bundled service. That may support adoption, but only if the allowed payment is adequate, claims are paid in practice, and clinicians see a meaningful diagnostic benefit. The announcement does not establish any of those conditions or quantify revenue impact for the manufacturer.

Near term, this is a modest positive read-through for PYLARIFY TruVu’s commercial pathway and potentially for competing agents if the policy signals broader support for separate reimbursement. Over the next 1–3 months, the key checks are the applicable payment rate, claims experience, and provider utilization—not the headline code change. The September 2029 endpoint creates a defined reimbursement horizon; it is not evidence of permanent economics, and could become a renewal or transition risk well before expiry. The contrarian point: investors may treat pass-through status as equivalent to guaranteed incremental sales, while the actual benefit depends on payment adequacy and uptake. With no company identity, exposure, or payment-rate data supplied, the signal is insufficient for a security-level recommendation.

Key Decisions for Investors

• No standalone trade on this announcement. First identify the manufacturer’s listed exposure and establish PYLARIFY TruVu’s contribution to revenue; neither is provided here.
• Set a 1–3 month diligence alert for the final payment amount, paid-claim evidence, and hospital/imaging-center utilization. Upgrade the thesis only if reimbursement is adequate and adoption is observable.
• Treat September 30, 2029 as a policy-duration boundary, not a guaranteed sales runway. Reassess if CMS signals an earlier payment change or if utilization fails to respond.
• Falsification: payment rates prove inadequate, claims are denied or delayed, or subsequent company disclosures show no meaningful uptake or revenue contribution.